| [1] |
European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)[J].Eur Heart J, 2011, 32(14): 1769-1818.
|
| [2] |
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2014, 63(25 Pt B): 2889-2934.
|
| [3] |
Expert Panel on Dyslipidemia. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia: executive summary[J]. Atherosclerosis, 2014, 232(2): 410-413.
|
| [4] |
Rabar S, Harker M, O'Flynn N, et al. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance[J]. BMJ, 2014, 349: g4356.
|
| [5] |
Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1——full report[J].J Clin Lipidol, 2015, 9(2): 129-169.
|
| [6] |
Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)[J]. Eur Heart J, 2014, 35(37): 2541-2619.
|
| [7] |
Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel Members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia——full report[J]. J Clin Lipidol, 2014, 8(1): 29-60.
|
| [8] |
中国成人血脂异常防治指南[J].中华心血管病杂志，2007，35（5）：390-419.
|
| [9] |
Jimenez-Navarro MF, Cabrera-Bueno F, Munoz-Garcia AJ, et al. Clinical trials and clinical practice in the real world. Do we know why efficacy is confused with effectiveness[J]? Rev Esp Cardiol, 2009, 62(3): 332-334.
|
| [10] |
Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials[J].Lancet, 2010, 376(9753): 1670-1681.
|
| [11] |
公威，聂绍平.欧美最新血脂管理指南解读:天壤之别还是异曲同工[J].中国医院用药评价与分析，2015，15（2）：153-156.
|
| [12] |
李建军.国际三项血脂治疗指南异同的初步解读[J].中国循环杂志，2015，30（1）：1-2.
|
| [13] |
刘淼，何耀.血脂防治指南述评及对我国临床实践的解析[J].中国药物应用与监测，2015，12（4）：197-200.
|
| [14] |
刘淼，何耀. 2013 ACC/AHA血脂防治指南的借鉴[J].中华心脏与心律电子杂志，2014，2（3）：8-9.
|
| [15] |
他汀类药物防治缺血性卒中/短暂性脑缺血发作专家共识组.他汀类药物防治缺血性卒中/短暂性脑缺血发作专家共识[J].中国卒中杂志，2013，8（7）：565-575.
|
| [16] |
Liao JK. Safety and efficacy of statins in Asians[J]. Am J Cardiol, 2007, 99(3): 410-414.
|
| [17] |
Gandelman K, Fung GL, Messig M, et al. Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies[J].Am J Ther, 2012, 19(3): 164-173.
|
| [18] |
血脂异常老年人使用他汀类药物中国专家共识组.血脂异常老年人使用他汀类药物中国专家共识[J].中华内科杂志，2015，54（5）：467-477.
|
| [19] |
他汀类药物安全性评价工作组.他汀类药物安全性评价专家共识[J].中华心血管病杂志，2014，42（11）：890-894.
|